Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CorMedix Inc.CRMD · Entity 5280 | Director · Chief Executive Officer | January 11, 2021 | January 14, 2021 |
| Longeveron Inc.LGVN · Entity 7608 | Director | August 11, 2025 | August 13, 2025 |
| Processa Pharmaceuticals, Inc.PCSA · Entity 8210 | Director | July 26, 2026 | July 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CorMedix Inc.
Report date January 11, 2021 · Filed January 14, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $8.32 · Expires 2031-01-11 | Direct | 320,000 |
Reported balance
After 2021-01-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-01-11 · Grant · Acquired 320,000 · Balance 320,000 F1: These options were granted on 1/11/2021. These options vest, subject to continued employment, as follows: 50% of the options vest over time, with 25% vested on the grant date and 25% vesting in equal thirds on the first, second and third anniversaries of the grant date; and 50% of the options vest upon the achievement of certain milestones. |
| Stock Option (Right to Buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $5.63 · Expires 2030-02-25 | Direct | 100,630 |
Reported balance
Holding disclosure · report date 2021-01-11 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 100,630 F2: These options were granted on 02/25/2020. These options vest 1/4 on the date of grant, 1/4 on the first anniversary of the date of grant, 1/4 on the second anniversary of the date of grant and 1/4 on the third anniversary of the date of grant. |
| Stock Option (Right to Buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $6.82 · Expires 2029-09-26 | Direct | 120,000 |
Reported balance
Holding disclosure · report date 2021-01-11 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 120,000 F3: The options will vest over four (4) years in four (4) equal annual installments on the first four (4) anniversaries of September 26, 2019, provided, in all cases, that Executive remains an employee of, or a consultant to, the Company through the applicable vesting date. |
| Stock Option (Right to Buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $8.30 · Expires 2029-01-10 | Direct | 69,600 |
Reported balance
Holding disclosure · report date 2021-01-11 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 69,600 F4: These options were granted on 1/10/2019. These options vest, subject to continued employment, as follows: 35% of the options vest over time, with 25% vested on the grant date and 25% vesting on the first, second and third anniversaries of the grant date; and 65% of the options vest upon the achievement of certain milestones. These options include options to purchase 7,000 shares that are subject to vesting each on January 10, 2021 and January 10, 2022. |
| Stock Option (Right to Buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $12.60 · Expires 2026-09-30 | Direct | 250,000 |
Reported balance
Holding disclosure · report date 2021-01-11 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 250,000 F5: These options were granted 9/30/2016. The option vests as follows: 25% on 10/3/2017, 25% on 10/3/2018, 25% on 10/3/2019, and 25% on 10/3/2020. |
| Stock Option (Right to Buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $12.60 · Expires 2026-09-30 | Direct | 60,000 |
Reported balance
Holding disclosure · report date 2021-01-11 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 60,000 F6: These options were granted 9/30/2016. The option vests based on certain performance milestones. If such milestones are met prior to 12/31/18, then the option will not vest until 12/31/18. The option will be forfeited if such milestones are not met by 10/3/2020. |
| Common StockSEC Table I · non-derivative | Direct | 60,905 |
Reported balance
Holding disclosure · report date 2021-01-11 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 60,905 |
Filing footnotes · ownership attribution and instrument terms
F1: These options were granted on 1/11/2021. These options vest, subject to continued employment, as follows: 50% of the options vest over time, with 25% vested on the grant date and 25% vesting in equal thirds on the first, second and third anniversaries of the grant date; and 50% of the options vest upon the achievement of certain milestones.
F2: These options were granted on 02/25/2020. These options vest 1/4 on the date of grant, 1/4 on the first anniversary of the date of grant, 1/4 on the second anniversary of the date of grant and 1/4 on the third anniversary of the date of grant.
F3: The options will vest over four (4) years in four (4) equal annual installments on the first four (4) anniversaries of September 26, 2019, provided, in all cases, that Executive remains an employee of, or a consultant to, the Company through the applicable vesting date.
F4: These options were granted on 1/10/2019. These options vest, subject to continued employment, as follows: 35% of the options vest over time, with 25% vested on the grant date and 25% vesting on the first, second and third anniversaries of the grant date; and 65% of the options vest upon the achievement of certain milestones. These options include options to purchase 7,000 shares that are subject to vesting each on January 10, 2021 and January 10, 2022.
F5: These options were granted 9/30/2016. The option vests as follows: 25% on 10/3/2017, 25% on 10/3/2018, 25% on 10/3/2019, and 25% on 10/3/2020.
F6: These options were granted 9/30/2016. The option vests based on certain performance milestones. If such milestones are met prior to 12/31/18, then the option will not vest until 12/31/18. The option will be forfeited if such milestones are not met by 10/3/2020.
Longeveron Inc.
Report date August 11, 2025 · Filed August 13, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 52,516 |
Reported balance
After 2025-08-11 transaction · row 1
1 source rowRow 1 · 2025-08-11 · Purchase · Acquired 11,766 · Balance 52,516 F1: The combined purchase price for each share of Class A Common Stock and accompanying two and one-half Class A Common Warrants was $0.85. |
| Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.85 · Expires 2027-08-11 | Direct | 29,415 |
Reported balance
After 2025-08-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-08-11 · Purchase · Acquired 29,415 · Balance 29,415 F1: The combined purchase price for each share of Class A Common Stock and accompanying two and one-half Class A Common Warrants was $0.85. |
Filing footnotes · ownership attribution and instrument terms
F1: The combined purchase price for each share of Class A Common Stock and accompanying two and one-half Class A Common Warrants was $0.85.
Processa Pharmaceuticals, Inc.
Report date July 26, 2026 · Filed July 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 38,749 |
Reported balance
After 2026-07-26 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-26 · Grant · Acquired 33,500 · Balance 38,749 F1: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death. F3: Reflects the 1-for-25 reverse stock split effected by the Issuer on December 17, 2025. |
| Common StockSEC Table I · non-derivative | Direct | 2,528 |
Reported balance
Holding disclosure · report date 2026-07-26 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 2,528 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.96 | Direct | 12,000 |
Reported balance
Holding disclosure · report date 2026-07-26 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 12,000 F2: Stock options vest one-third on the first anniversary date of the grant, with the remaining options vesting ratably over the subsequent two years. F3: Reflects the 1-for-25 reverse stock split effected by the Issuer on December 17, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death.
F2: Stock options vest one-third on the first anniversary date of the grant, with the remaining options vesting ratably over the subsequent two years.
F3: Reflects the 1-for-25 reverse stock split effected by the Issuer on December 17, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 26, 2026 Filed Jul 29, 2026 00:19 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 33,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-26-001546 · form4.xml · derivative · entry 2 Baluch Khoso · CIK 0001686223 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,749 Underlying: Common Stock · 33,500 shares Expires not disclosed F1 · shares: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death. F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death. F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death. F3 · balance_after: Reflects the 1-for-25 reverse stock split effected by the Issuer on December 17, 2025. Read SEC document |
| June 26, 2026 Filed Jun 30, 2026 20:46 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Exercise / conversionRestricted Stock · Derivative | 203 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-26-001466 · form4.xml · derivative · entry 2 Baluch Khoso · CIK 0001686223 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,249 Underlying: Common Stock · 203 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Distribution of time-based service award. F1 · derivative.expiration_date: Distribution of time-based service award. Read SEC document |
| June 26, 2026 Filed Jun 30, 2026 20:46 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Exercise / conversionCommon Stock | 203 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000897069-26-001466 · form4.xml · nonDerivative · entry 1 Baluch Khoso · CIK 0001686223 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,528 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Distribution of time-based service award. Read SEC document |
| March 31, 2026 Filed Apr 1, 2026 21:06 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | PurchaseCommon Stock | 2,269 | $2.54 | $5,751.92 |
DisclosureSEC source: 0000897069-26-000741 · form4.xml · nonDerivative · entry 1 Baluch Khoso · CIK 0001686223 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,325 Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 20:39 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantStock Options (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $0.20 | $0.00 |
DisclosureSEC source: 0000897069-25-001559 · form4.xml · derivative · entry 2 Baluch Khoso · CIK 0001686223 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires not disclosed F2 · derivative.exercise_date: Stock options vest one-third on the first anniversary date of the grant, with the remaining options vesting ratably over the subsequent two years. F2 · derivative.expiration_date: Stock options vest one-third on the first anniversary date of the grant, with the remaining options vesting ratably over the subsequent two years. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 20:39 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 100,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-25-001559 · form4.xml · derivative · entry 1 Baluch Khoso · CIK 0001686223 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires not disclosed F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on October 1, 2026, and one-thirty-sixth each month thereafter until fully vested on October 1, 2028. F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on October 1, 2026, and one-thirty-sixth each month thereafter until fully vested on October 1, 2028. Read SEC document |
| August 11, 2025 Filed Aug 13, 2025 22:00 UTC | Longeveron Inc. LGVN · Entity 7608 | PurchaseWarrant (right to buy) · Derivative | 29,415 | Not disclosed Strike: $0.85 | Not disclosed |
DisclosureSEC source: 0001214659-25-012013 · marketforms-70282.xml · derivative · entry 2 Baluch Khoso · CIK 0001686223 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,415 Underlying: Class A Common Stock · 29,415 shares Expires 2027-08-11 F1 · price: The combined purchase price for each share of Class A Common Stock and accompanying two and one-half Class A Common Warrants was $0.85. Read SEC document |
| August 11, 2025 Filed Aug 13, 2025 22:00 UTC | Longeveron Inc. LGVN · Entity 7608 | PurchaseClass A Common Stock | 11,766 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001214659-25-012013 · marketforms-70282.xml · nonDerivative · entry 1 Baluch Khoso · CIK 0001686223 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,516 F1 · price: The combined purchase price for each share of Class A Common Stock and accompanying two and one-half Class A Common Warrants was $0.85. Read SEC document |
| July 24, 2025 Filed Jul 28, 2025 20:19 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock · Derivative | 175,299 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-25-001209 · form4.xml · derivative · entry 1 Baluch Khoso · CIK 0001686223 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 206,505 Underlying: Common Stock · 175,299 shares Expires not disclosed F1 · shares: Restricted stock granted under the Processa Pharmaceuticals, Inc. 2019 Omnibus Incentive Plan ("Omnibus Plan"), of which 125,999 shares are subject to stockholder approval of the revised Omnibus Plan. F2 · derivative.exercise_date: The restricted stock vest on the earlier of June 30, 2026 or the next annual meeting of stockholders, subject to certain distribution requirements. F2 · derivative.expiration_date: The restricted stock vest on the earlier of June 30, 2026 or the next annual meeting of stockholders, subject to certain distribution requirements. Read SEC document |
| July 15, 2025 Filed Jul 17, 2025 23:45 UTC | Longeveron Inc. LGVN · Entity 7608 | GrantClass A Common Stock | 17,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-25-010570 · marketforms-70111.xml · nonDerivative · entry 1 Baluch Khoso · CIK 0001686223 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,750 F1 · shares: Represents the award of time-based vesting Restricted Stock Units (RSUs). F2 · balance_after: Includes RSUs subject to future vesting. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 23:00 UTC | Longeveron Inc. LGVN · Entity 7608 | SaleClass A Common Stock | 1,250 | $2.07 | $2,588.13 |
DisclosureSEC source: 0001214659-24-019977 · marketforms-67491.xml · nonDerivative · entry 1 Baluch Khoso · CIK 0001686223 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,750 F1 · balance_after: A previously filed Form 4 mistakenly under-reported the level of Class A Common Stock owned, as the amount did not account for the one-for-ten stock split that occurred in April 2024 otherwise under-reported by 125 shares. The under-reporting was the result of another previously filed Form 4 which mistakenly reported a disposition of these shares for tax purposes. Thus, the reporting person beneficially owned 25,000 shares of Class A Common Stock before the December 2, 2024 sale reported in this Form 4, which is accounted for in the amount reported in this column 5. F2 · balance_after: Includes Restricted Stock Units (RSUs) subject to future vesting. Read SEC document |
| September 03, 2024 Filed Sep 18, 2024 20:47 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock · Derivative | 31,206 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-24-001860 · form4.xml · derivative · entry 1 Baluch Khoso · CIK 0001686223 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,206 Underlying: Common Stock · 31,206 shares Expires not disclosed F1 · derivative.exercise_date: The restricted stock vest on the earlier of June 28, 2025 or the next annual meeting of stockholders, subject to certain distribution requirements. F1 · derivative.expiration_date: The restricted stock vest on the earlier of June 28, 2025 or the next annual meeting of stockholders, subject to certain distribution requirements. Read SEC document |
| September 03, 2024 Filed Sep 18, 2025 20:12 UTC Amendment | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock · Derivative | 31,206 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-25-001488 · form4.xml · derivative · entry 1 Baluch Khoso · CIK 0001686223 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,275 Underlying: Common Stock · 31,206 shares Expires not disclosed F1 · derivative.exercise_date: The restricted stock vest on the earlier of June 28, 2025 or the next annual meeting of stockholders, subject to certain distribution requirements. F1 · derivative.expiration_date: The restricted stock vest on the earlier of June 28, 2025 or the next annual meeting of stockholders, subject to certain distribution requirements. F2 · balance_after: Amending to correct the beneficially owned shares reported on the Form 4 filed September 18, 2024. Read SEC document |
| August 15, 2024 Filed Aug 20, 2024 00:30 UTC | Longeveron Inc. LGVN · Entity 7608 | GrantClass A Common Stock | 23,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-24-014990 · marketforms-66802.xml · nonDerivative · entry 1 Baluch Khoso · CIK 0001686223 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,375 F1 · shares: Represents the award of time-based vesting Restricted Stock Units (RSUs). F2 · balance_after: Includes RSUs subject to future vesting. Read SEC document |
| June 09, 2024 Filed Jun 11, 2024 21:00 UTC | Longeveron Inc. LGVN · Entity 7608 | Tax withholdingCommon Stock | 125 | $1.06 | $132.50 |
DisclosureSEC source: 0001214659-24-010840 · marketforms-66330.xml · nonDerivative · entry 1 Baluch Khoso · CIK 0001686223 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,875 F1 · shares: Shares withheld to satisfy the tax obligations in connection with the vesting of a restricted stock unit award. Read SEC document |
| December 29, 2023 Filed Jan 2, 2024 23:00 UTC | Longeveron Inc. LGVN · Entity 7608 | PurchaseCommon Stock | 8,322 | $1.43 | $11,914.61 |
DisclosureSEC source: 0001214659-24-000079 · marketforms-63954.xml · nonDerivative · entry 2 Baluch Khoso · CIK 0001686223 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 F1 · price: The price per share reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.39 to $1.45, inclusive. The reporting person undertakes to provide to Longeveron Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| December 28, 2023 Filed Jan 2, 2024 23:00 UTC | Longeveron Inc. LGVN · Entity 7608 | PurchaseCommon Stock | 1,678 | $1.40 | $2,341.98 |
DisclosureSEC source: 0001214659-24-000079 · marketforms-63954.xml · nonDerivative · entry 1 Baluch Khoso · CIK 0001686223 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,678 Read SEC document |
| December 21, 2023 Filed Dec 26, 2023 23:00 UTC | Longeveron Inc. LGVN · Entity 7608 | GrantStock Option (Right to buy) · Derivative | 12,000 | $0.00 Strike: $1.25 | $0.00 |
DisclosureSEC source: 0001214659-23-016872 · marketforms-63913.xml · derivative · entry 1 Baluch Khoso · CIK 0001686223 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2033-12-21 F1 · derivative.exercise_date: The option vests in four equal annual installments beginning on first anniversary of date of grant. Read SEC document |
| June 27, 2023 Filed Jul 24, 2023 22:29 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock · Derivative | 101,365 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-23-001000 · form4.xml · derivative · entry 3 Baluch Khoso · CIK 0001686223 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,365 Underlying: Common Stock · 101,365 shares Expires not disclosed F2 · derivative.exercise_date: The restricted stock vests on the earliest of one year from date of grant or the next annual meeting of stockholders. F2 · derivative.expiration_date: The restricted stock vests on the earliest of one year from date of grant or the next annual meeting of stockholders. Read SEC document |
| June 27, 2023 Filed Jul 24, 2023 22:29 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Exercise / conversionRestricted Stock · Derivative | 15,455 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-23-001000 · form4.xml · derivative · entry 2 Baluch Khoso · CIK 0001686223 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,455 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Vesting of time-based restricted shares. F1 · derivative.expiration_date: Vesting of time-based restricted shares. Read SEC document |
| June 27, 2023 Filed Jul 24, 2023 22:29 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Exercise / conversionCommon Stock | 15,455 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000897069-23-001000 · form4.xml · nonDerivative · entry 1 Baluch Khoso · CIK 0001686223 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,955 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Vesting of time-based restricted shares. Read SEC document |
| June 09, 2023 Filed Jun 12, 2023 21:15 UTC | Longeveron Inc. LGVN · Entity 7608 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-23-008428 · marketforms-61769.xml · nonDerivative · entry 1 Baluch Khoso · CIK 0001686223 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 F1 · shares: Represents a grant of Restricted Stock Units subject to time-based vesting. F2 · balance_after: Includes 5,000 Restricted Stock Units. Read SEC document |
| February 09, 2023 Filed Feb 10, 2023 22:18 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantCommon Stock | 12,500 | $0.80 | $10,000.00 |
DisclosureSEC source: 0001567619-23-002401 · doc1.xml · nonDerivative · entry 1 Baluch Khoso · CIK 0001686223 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Read SEC document |
| July 12, 2022 Filed Jul 14, 2022 20:24 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock · Derivative | 19,091 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-014019 · doc1.xml · derivative · entry 1 Baluch Khoso · CIK 0001686223 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,091 Underlying: Common Stock · 19,091 shares Expires not disclosed F1 · derivative.exercise_date: The restricted stock vest on the earlier of one year from the grant date or the next annual meeting of stockholders. F1 · derivative.expiration_date: The restricted stock vest on the earlier of one year from the grant date or the next annual meeting of stockholders. Read SEC document |
| January 11, 2021 Filed Jan 14, 2021 01:07 UTC | CorMedix Inc. CRMD · Entity 5280 | GrantStock Option (Right to Buy Common Stock) · Derivative | 320,000 | $0.00 Strike: $8.32 | $0.00 |
DisclosureSEC source: 0001213900-21-002054 · doc4.xml · derivative · entry 2 Baluch Khoso · CIK 0001686223 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 320,000 Underlying: Common Stock · 320,000 shares Expires 2031-01-11 F1 · derivative.exercise_date: These options were granted on 1/11/2021. These options vest, subject to continued employment, as follows: 50% of the options vest over time, with 25% vested on the grant date and 25% vesting in equal thirds on the first, second and third anniversaries of the grant date; and 50% of the options vest upon the achievement of certain milestones. Read SEC document |
| August 13, 2020 Filed Aug 17, 2020 22:45 UTC | CorMedix Inc. CRMD · Entity 5280 | PurchaseCommon Stock | 4,830 | $4.14 | $19,985.09 |
DisclosureSEC source: 0001213900-20-022546 · doc4.xml · nonDerivative · entry 1 Baluch Khoso · CIK 0001686223 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,905 F1 · price: This transaction was executed in multiple trades at prices ranging from $4.1297 to $4.14. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| March 18, 2020 Filed Mar 18, 2020 20:25 UTC | CorMedix Inc. CRMD · Entity 5280 | PurchaseCommon Stock | 3,500 | $2.61 | $9,135.00 |
DisclosureSEC source: 0001213900-20-006779 · doc4.xml · nonDerivative · entry 1 Baluch Khoso · CIK 0001686223 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,075 Read SEC document |
| February 25, 2020 Filed Feb 28, 2020 02:46 UTC | CorMedix Inc. CRMD · Entity 5280 | GrantStock Option (Right to Buy Common Stock) · Derivative | 100,630 | $5.63 Strike: $5.63 | $566,546.90 |
DisclosureSEC source: 0001213900-20-004977 · doc4.xml · derivative · entry 2 Baluch Khoso · CIK 0001686223 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,630 Underlying: Common Stock · 100,630 shares Expires 2030-02-25 F1 · derivative.exercise_date: These options were granted on 02/25/2020. These options vest 1/4 on the date of grant, 1/4 on the first anniversary of the date of grant, 1/4 on the second anniversary of the date of grant and 1/4 on the third anniversary of the date of grant. Read SEC document |
| September 26, 2019 Filed Sep 30, 2019 20:08 UTC | CorMedix Inc. CRMD · Entity 5280 | GrantStock Option (Right to Buy Common Stock) · Derivative | 120,000 | $0.00 Strike: $6.82 | $0.00 |
DisclosureSEC source: 0001213900-19-019299 · ownership.xml · derivative · entry 2 Baluch Khoso · CIK 0001686223 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2029-09-26 F1 · derivative.exercise_date: The options will vest over four (4) years in four (4) equal annual installments on the first four (4) anniversaries of September 26, 2019, provided, in all cases, that Executive remains an employee of, or a consultant to, the Company through the applicable vesting date. Read SEC document |
| March 26, 2019 Filed Mar 27, 2019 20:15 UTC | CorMedix Inc. CRMD · Entity 5280 | PurchaseCommon Stock | 2,500 | $7.55 | $18,875.00 |
DisclosureSEC source: 0001654954-19-003467 · section16.xml · nonDerivative · entry 1 Baluch Khoso · CIK 0001686223 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,575 F1 · balance_after: The Issuer effected a 1-for-5 reverse stock split of its common stock on March 26, 2019. All share and per share exercise price amounts shown in this Form 4 have been adjusted to reflect the reverse stock split. Read SEC document |
| January 10, 2019 Filed Jan 11, 2019 21:22 UTC | CorMedix Inc. CRMD · Entity 5280 | GrantStock Option (Right to Buy Common Stock) · Derivative | 400,000 | $0.00 Strike: $1.66 | $0.00 |
DisclosureSEC source: 0001654954-19-000386 · section16.xml · derivative · entry 2 Baluch Khoso · CIK 0001686223 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2029-01-10 F1 · derivative.exercise_date: These options were granted on 1/10/2019. These options vest, subject to continued employment, as follows: 35% of the options vest over time, with 25% vested on the grant date and 25% vesting on the first, second and third anniversaries of the grant date; and 65% of the options vest upon the achievement of certain milestones. Read SEC document |
| November 27, 2018 Filed Nov 27, 2018 21:55 UTC | CorMedix Inc. CRMD · Entity 5280 | PurchaseCommon Stock | 21,500 | $1.21 | $26,015.00 |
DisclosureSEC source: 0001654954-18-013261 · section16.xml · nonDerivative · entry 1 Baluch Khoso · CIK 0001686223 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,373 F1 · price: Represents the weighted average purchase price of the shares purchased ranging from a low of $1.21 to a high of $1.22 per share. Read SEC document |
| November 26, 2018 Filed Nov 27, 2018 21:55 UTC | CorMedix Inc. CRMD · Entity 5280 | PurchaseCommon Stock | 3,500 | $1.28 | $4,480.00 |
DisclosureSEC source: 0001654954-18-013261 · section16.xml · nonDerivative · entry 2 Baluch Khoso · CIK 0001686223 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,873 Read SEC document |
| February 16, 2018 Filed Feb 20, 2018 21:01 UTC | CorMedix Inc. CRMD · Entity 5280 | GrantStock Option (Right to Buy Common Stock) · Derivative | 225,000 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001654954-18-001715 · section16.xml · derivative · entry 2 Baluch Khoso · CIK 0001686223 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2028-02-16 F1 · derivative.exercise_date: The options vest 25% on the date of grant (2/16/2018), and 25% on the first, second and third anniversaries of the date of grant, subject to Optionee's continued service through such date. Read SEC document |
| December 12, 2017 Filed Dec 14, 2017 21:06 UTC | CorMedix Inc. CRMD · Entity 5280 | PurchaseCommon Stock | 104,166 | $0.48 | $49,999.68 |
DisclosureSEC source: 0001654954-17-011648 · section16.xml · nonDerivative · entry 1 Baluch Khoso · CIK 0001686223 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,373 F1 · date: Purchase was contracted on November 17, 2017, but not closed until December 12, 2017. Read SEC document |
| August 18, 2017 Filed Aug 22, 2017 20:03 UTC | CorMedix Inc. CRMD · Entity 5280 | PurchaseCommon Stock | 36,207 | $0.42 | $15,025.91 |
DisclosureSEC source: 0001654954-17-007836 · section16.xml · nonDerivative · entry 1 Baluch Khoso · CIK 0001686223 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,207 Read SEC document |
| May 17, 2017 Filed May 19, 2017 20:05 UTC | CorMedix Inc. CRMD · Entity 5280 | PurchaseCommon Stock | 75,000 | $0.48 | $35,625.00 |
DisclosureSEC source: 0001354488-17-000530 · issuerdirect_section16.xml · nonDerivative · entry 1 Baluch Khoso · CIK 0001686223 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Read SEC document |
| December 09, 2016 Filed Dec 13, 2016 21:01 UTC | CorMedix Inc. CRMD · Entity 5280 | PurchaseCommon Stock | 10,000 | $1.77 | $17,700.00 |
DisclosureSEC source: 0001354488-16-008655 · issuerdirect_section16.xml · nonDerivative · entry 1 Baluch Khoso · CIK 0001686223 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Read SEC document |
| October 03, 2016 Filed Oct 5, 2016 20:50 UTC | CorMedix Inc. CRMD · Entity 5280 | GrantStock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $2.52 | $0.00 |
DisclosureSEC source: 0001354488-16-008364 · issuerdirect_section16.xml · derivative · entry 3 Baluch Khoso · CIK 0001686223 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2026-10-03 F3 · derivative.exercise_date: The option vests based on certain performance milestones. If such milestones are met prior to 12/31/18, then the option will not vest until 12/31/18. The option will be forfeited if such milestones are not met by 10/3/2020. Read SEC document |
| October 03, 2016 Filed Oct 5, 2016 20:50 UTC | CorMedix Inc. CRMD · Entity 5280 | GrantStock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $2.52 | $0.00 |
DisclosureSEC source: 0001354488-16-008364 · issuerdirect_section16.xml · derivative · entry 2 Baluch Khoso · CIK 0001686223 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2026-10-03 F2 · derivative.exercise_date: The option vests on the date the Company?s common stock attains an average closing price over any period of 30 consecutive trading days equal to or greater than 2.75 times the closing price per share on the lesser of 9/23/16 or 10/3/16 (the ?Stock Price Condition"); provided, that if the Stock Price Condition is met prior to 12/31/18 then the option will not vest until 12/31/18. The option will be forfeited (i) if the stock price on 12/31/18 is below the closing price per share on the lesser of 9/23/16 or 10/3/16, or (ii) if the Stock Price Condition is not met by 10/3/2020. Read SEC document |
| October 03, 2016 Filed Oct 5, 2016 20:50 UTC | CorMedix Inc. CRMD · Entity 5280 | GrantStock Option (right to buy) · Derivative | 1,250,000 | $0.00 Strike: $2.52 | $0.00 |
DisclosureSEC source: 0001354488-16-008364 · issuerdirect_section16.xml · derivative · entry 1 Baluch Khoso · CIK 0001686223 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,250,000 Underlying: Common Stock · 1,250,000 shares Expires 2026-10-03 F1 · derivative.exercise_date: The option vests as follows: 25% on 10/3/2017, 25% on 10/3/2018, 25% on 10/3/2019, and 25% on 10/3/2020. Read SEC document |
| October 03, 2016 Filed Oct 11, 2016 14:37 UTC Amendment | CorMedix Inc. CRMD · Entity 5280 | GrantStock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $2.52 | $0.00 |
DisclosureSEC source: 0001354488-16-008375 · issuerdirect_section16.xml · derivative · entry 3 Baluch Khoso · CIK 0001686223 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2026-09-30 F3 · derivative.exercise_date: The option vests based on certain performance milestones. If such milestones are met prior to 12/31/18, then the option will not vest until 12/31/18. The option will be forfeited if such milestones are not met by 10/3/2020. Read SEC document |
| October 03, 2016 Filed Oct 11, 2016 14:37 UTC Amendment | CorMedix Inc. CRMD · Entity 5280 | GrantStock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $2.52 | $0.00 |
DisclosureSEC source: 0001354488-16-008375 · issuerdirect_section16.xml · derivative · entry 2 Baluch Khoso · CIK 0001686223 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2026-09-30 F2 · derivative.exercise_date: The option vests on the date the Company?s common stock attains an average closing price over any period of 30 consecutive trading days equal to or greater than 2.75 times the closing price per share on the lesser of 9/23/16 or 10/3/16 (the ?Stock Price Condition"); provided, that if the Stock Price Condition is met prior to 12/31/18 then the option will not vest until 12/31/18. The option will be forfeited (i) if the stock price on 12/31/18 is below the closing price per share on the lesser of 9/23/16 or 10/3/16, or (ii) if the Stock Price Condition is not met by 10/3/2020. Read SEC document |
| October 03, 2016 Filed Oct 11, 2016 14:37 UTC Amendment | CorMedix Inc. CRMD · Entity 5280 | GrantStock Option (right to buy) · Derivative | 1,250,000 | $0.00 Strike: $2.52 | $0.00 |
DisclosureSEC source: 0001354488-16-008375 · issuerdirect_section16.xml · derivative · entry 1 Baluch Khoso · CIK 0001686223 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,250,000 Underlying: Common Stock · 1,250,000 shares Expires 2026-09-30 F1 · derivative.exercise_date: The option vests as follows: 25% on 10/3/2017, 25% on 10/3/2018, 25% on 10/3/2019, and 25% on 10/3/2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.